Overview

Cisplatin+Pembrolizumab+RT in Vulvar Cancer

Status:
Recruiting
Trial end date:
2025-01-30
Target enrollment:
Participant gender:
Summary
This research is being done to see how well the combination of a standard of care drug, investigational drug, and radiation therapy work against unresectable vulvar squamous cell carcinoma. This research study involves the following: - Cisplatin (standard of care drug) - Pembrolizumab (investigational drug) - Radiation Therapy (standard of care intervention)
Phase:
Phase 2
Details
Lead Sponsor:
Massachusetts General Hospital
Collaborator:
Merck Sharp & Dohme Corp.
Treatments:
Cisplatin
Pembrolizumab